Close

Testimony before House Energy and Commerce Subcommittee on Health

Jul 7 2011
Paul Hastings, testifying on behalf of BIO, discussed the importance of biotechnology in providing cures to diseases, and creating high-paying jobs.

BIO Comments on Proposed Rule Establishing an Influenza Vaccination Standard for Certain Medicare and Medicaid Providers and Suppliers

Jul 5 2011

...

Jim Greenwood's Address at the 2011 BIO International Convention

Jun 28 2011

...

Comments on Periodic Review of Existing Regulations; Retrospective Review under Executive Order 13563

Jun 27 2011

...

Address by H.R.H. Prince Philippe of Belgium to the 2011 BIO International Convention

Jun 27 2011

BIO Testimony to the House Agriculture Subcommittee on Rural Development, Research, Biotechnology, and Foreign Agriculture

Jun 23 2011

...

BIO’s Comments on the Internal Revenue Service's (IRS) Proposed Guidance Regarding the Branded Prescription Drug Fee

Jun 15 2011
BIO’s comments reiterated concerns with widespread data issues that were expressed in BIO’s April 2011 comment letter. BIO provided suggestions to improve the transparency of the assessment process.

American Invents Act Manager's Amendment: BIO Strongly Supports

Jun 14 2011
The legislation would end the diversion of fees collected by the U.S. Patent and Trademark Office, increase the objectivity of our patent system, and increase patent quality. It is precisely these types of reforms that should receive bipartisan support, as they are good for inventors and investors, hence good for business and jobs in America.

Fee Diversion: BIO Joins Broad Coalition to Support End of Fee Diversion at PTO

Jun 13 2011
Absent a statutory mechanism to prevent future fee diversion, the existing and new responsibilities vested in the U.S. Patent and Trademark Office (PTO) will suffer, the ability of the PTO to plan long-term and build the agency our innovation economy demands will be frustrated, and the job-stifling patent application backlog will continue.

BIO Submits Comments to FDA on "Biologics Price Competition and Innovation Act of 2009 (BPCIA)

Jun 9 2011
BIO generally supports and agrees with FDA's statements that existing user fee programs can inform the Agency's development of a user fee program for 351(k) applications, and that the establishment of user fees for products subject to the 351(k) pathway also presents unique challenges compared to existing programs.